2025 Education Partner Program: Where Are We with Cardiac Amyloidosis
The goal of this activity is to improve the heart failure clinician's awareness and knowledge of Transthyretin Cardiac Amyloidosis (ATTR_CA) and the associated risks of heart failure. This increased knowledge will include a better understanding of the important role of new and emerging RNA interference (RNAi) therapies for the management of Hereditary Transthyretin Cardiac Amyloidosis (hATTR-CA); and the optimal use of TTR stabilizers and TTR silencers/knockdown agents along with heart failure and arrhythmia management.
Target Audience
This activity is intended for physicians, nurses, nurse practitioners, physician assistants, and pharmacists.
Learning Objectives
The learning objectives for the proposed activity are based on the identified gaps and are designed to assess the participant's knowledge and competence. The objectives are:
1. Review the current practice on the diagnosis and initiation of treatment for patients with ATTR-CA
2. Evaluate the current and emerging data on new therapies for the treatment of ATTR-CA
3. Discuss the clinical trial data and the role of RNAi therapies in the management of patients with ATTR-CA
Agenda
|
AGENDA
|
|
Welcome/Introduction
Justin Grodin, MD, MPH, FACC, FHFSA
|
|
ATTR Diagnosis: Current Best Practices and Emerging Horizons – Exploring Novel Techniques, Non-Invasive Approaches, and Biomarkers
Justin Grodin, MD, MPH, FACC, FHFSA
|
|
Breaking Ground: The Latest Data and Game-Changing Therapies in ATTR
Kevin Alexander, MD, FACC, FHFSA
|
|
ATTR in Focus: Engaging Case Vignettes and Real-World Insights
Amy Brownell, MSN, FNP-C, FACC
|
|
Panel Discussion
All
|
|
Closing Remarks/Adjourn
Justin Grodin, MD, MPH, FACC, FHFSA
|
Faculty Disclosures
The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.
Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.
Faculty
The following faculty and/or accreditors with the ability to control content for this activity have listed the below disclosures:
- Justin L. Grodin, MD, MPH, FACC, FHFSA: Consulting: Pfizer, Eidos/BridgeBio, AstraZeneca, Intellia Therapeutics, Tenax Therapeutics, Alexion, Novo Nordisk, Lumanity, Ultromics, and Alnylam. Grant Support: Texas Health Resources Clinical Scholarship, Eidos/BridgeBio, Pfizer 67656485, and NHLBI R01HL160892.
- Kevin Alexander, MD, FACC, FHFSA: Alnylam Pharmaceuticals, Eidos Therapeutics, Pfizer, Ionis Pharmaceuticals, Arbor Biotechnologies, Novo Nordisk, Bristol-Myers Squibb.
- Amy Brownell, MSN, FNP-C, FACC: Alnylam Pharmaceuticals, Bristol-Myers Squibb, BridgeBio, Cytokinetics.
The following faculty and/or accreditors with the ability to control content for this activity have no conflict of interest:
- Margaret A. Clark, MSc, MLitt, RN, RRT - NPS, CMPP (Medical Writer/Planner)
- Shauna Brown-Wheeler, MSL (CE Reviwer)
Off-Label Disclosure
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
Accreditation Statement
Physicians: In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The Heart Failure Society of America designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Learners should claim on the credit commensurate with the extent of their participation in the activity.
Nurses: This educational activity is approved for continuing nursing education (CNE) units by the HFSA, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 1.50 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists: The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is accredited for 1.50 contact hours of knowledge-based CPE under the ACPE universal activity number (UAN): JA4008267-0000-25-001-L01-P (live attendance only); JA4008267-0000-24-017-H01-P (on-demand/home study)
Physician Associates: The Heart Failure Society of America has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Learners should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity is supported by an educational grant from Alnylam Pharmaceuticals.
Important Date(s)
Originally recorded January 23, 2025